Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
- Promising weight loss data showing up to 14.2% reduction with MET-097i
- Strong cash position of $588.3 million providing runway into 2027
- Successful completion of $316 million IPO
- Multiple clinical trial milestones expected throughout 2025
- Strategic manufacturing collaboration with Amneal progressing on schedule
- Increased net loss to $76.6 million in Q1 2025 from $19.9 million in Q1 2024
- R&D expenses significantly increased to $57.2 million from $17.8 million year-over-year
- G&A expenses doubled to $8.6 million from $4.1 million year-over-year
Insights
Metsera reports strong cash position and advancing obesity pipeline with key data readouts approaching in 2025.
Metsera's Q1 2025 earnings report reveals a solid financial foundation with
The company's lead candidate, MET-097i, a monthly GLP-1 receptor agonist, has demonstrated compelling early efficacy with weight loss up to
What's particularly noteworthy is Metsera's multi-pronged approach to the obesity market. Beyond their injectable candidate, they're advancing MET-233i (an amylin analog) with data expected in Q2 2025, and accelerating oral GLP-1 formulations with data expected late 2025. This diversified portfolio approach provides multiple shots on goal in the rapidly growing obesity therapeutics market.
The sharp increase in R&D spending (
Their manufacturing collaboration with Amneal is strategically important, establishing dedicated peptide synthesis and sterile fill-finish capabilities that will be crucial for scaling commercial production if their products reach approval. This forward-looking infrastructure investment demonstrates management's confidence in their clinical assets and reduces future commercialization risks.
Metsera's obesity pipeline shows promising clinical progress with multiple near-term catalysts across injectable and oral GLP-1 programs.
Metsera's clinical pipeline demonstrates sophisticated targeting of obesity pathways with several distinctive technological advantages. Their lead candidate MET-097i employs an ultra-long acting formulation enabling monthly dosing, which represents a significant potential improvement over weekly GLP-1 injections currently dominating the market. The reported
The company's three-trial VESPER Phase 2b program is methodically designed to establish efficacy in both obesity alone (VESPER-1) and with comorbid type 2 diabetes (VESPER-2), while specifically evaluating monthly dosing (VESPER-3). This comprehensive approach should generate robust data packages for regulatory discussions and potential partnership negotiations.
Their parallel development of MET-233i, an ultra-long acting amylin analog, is particularly intriguing from a scientific perspective. Amylin analogs target a complementary mechanism to GLP-1s, and the company's co-administration studies could potentially demonstrate synergistic weight loss effects that exceed standalone GLP-1 therapy. This represents a potential differentiation strategy in an increasingly competitive market.
The acceleration of their oral program with MET-097o suggests promising preclinical bioavailability data, addressing the key challenge in oral peptide delivery. Their approach of advancing two oral candidates simultaneously (MET-097o and MET-224o) with a decision point based on Phase 1 performance is a disciplined strategy to mitigate development risk while pursuing the highly attractive oral obesity medication market.
The manufacturing collaboration with Amneal providing dedicated peptide synthesis capacity is a critical strategic advantage, as manufacturing constraints have been a significant limitation for other companies in the GLP-1 space.
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025
MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025
MET-097o, an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224o is on track, with four-week data for selected lead expected in late 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported first quarter 2025 financial results and continued portfolio progress.
“The first quarter of 2025 was a period of focused execution and acceleration at Metsera,” said Whit Bernard, Chief Executive Officer of Metsera. “We remain on track to deliver on all of our committed clinical milestones for 2025, including five-week data for our ultra-long acting amylin analog MET-233i in Q2, 28-week data for our ultra-long acting GLP-1 RA MET-097i by mid-year, and multiple additional clinical readouts of our injectable and oral programs by year-end.”
Chris Visioli, Chief Financial Officer, added: “In the first quarter of 2025, we successfully completed a
Pipeline Highlights and Upcoming Milestones
MET-097i: Phase 2b program on track, with Phase 3 initiation planned in late 2025
- MET-097i is a fully biased, monthly, ultra-long acting, subcutaneously injectable GLP-1 receptor agonist (RA). In early 2025, we disclosed competitive body weight loss and differentiated tolerability data for MET-097i after twelve weekly doses, with favorable tolerability and continued weight loss up to
14.2% after a thirteenth, potential monthly dose. We plan to release additional results from this trial at the American Diabetes Association’s (ADA) 85th Scientific Sessions, in addition to several other presentations focused on MET-097i. - The VESPER program includes three ongoing Phase 2b trials designed to further evaluate the differentiated profile of MET-097i, and enable rapid transition into Phase 3 clinical trials:
- VESPER-1 is designed to assess weight loss of different weekly doses of MET-097i over 28 weeks in participants with obesity or overweight without type 2 diabetes. The trial was fully enrolled as of end-2024, and preliminary results are expected in mid-2025.
- VESPER-2 is designed to assess weight loss and tolerability of different weekly doses of MET-097i over 28 weeks in participants with type 2 diabetes and obesity or overweight. Preliminary results are expected in early 2026.
- VESPER-3 is designed to assess weight loss and tolerability of multiple monthly doses of MET-097i after 12 initial weekly doses in individuals with obesity or overweight without type 2 diabetes. Preliminary results are expected by year-end 2025 or in early 2026.
- VESPER-1 is designed to assess weight loss of different weekly doses of MET-097i over 28 weeks in participants with obesity or overweight without type 2 diabetes. The trial was fully enrolled as of end-2024, and preliminary results are expected in mid-2025.
- Pending VESPER-1 results, we remain on track to initiate a Phase 3 program of MET-097i in late 2025.
MET-233i: Five-week monotherapy data readout expected in Q2 2025, with additional monotherapy and co-administration readouts planned in late 2025
- MET-233i is a monthly, ultra-long acting, subcutaneously injectable amylin analog in ongoing Phase 1 trials as a monotherapy and co-administered with MET-097i.
- Preliminary five-week weight loss, tolerability, and pharmacokinetic data from the monotherapy Phase 1 trial are expected in Q2 2025, and 12-week data from this trial are expected in late 2025.
- Preliminary five-week weight loss, tolerability, and pharmacokinetic data from the Phase 1 co-administration trial are expected in late 2025.
Oral peptide platform: MET-097o oral program accelerated and alternate oral candidate MET-224o on track; four-week data for selected lead expected in late 2025
- MET-097o and MET-224o are oral, fully biased, ultra-long acting GLP-1 receptor agonists in development for the treatment of obesity and overweight.
- Our ongoing Phase 1 formulation optimization study using prototype oral GLP-1 receptor agonist MET-002o is on track.
- Promising preclinical oral exposure data for MET-097o, combined with the compelling clinical profile of injectable MET-097i, have led us to accelerate MET-097o as a potential lead oral candidate.
- We plan to initiate Phase 1 trials of MET-097o and MET-224o in mid-2025, and to select and advance the best-performing oral candidate based on the Phase 1 clinical data. Preliminary four-week weight loss, tolerability, and pharmacokinetic data for the selected lead candidate are expected in late 2025.
First Quarter 2025 Financial Results
Cash Position: Cash and cash equivalents were
R&D Expenses: Research and development (R&D) expenses were
G&A Expenses: General and administrative (G&A) expenses were
Net Loss: Net loss was
Manufacturing Updates
Amneal strategic collaboration advancing as part of Metsera’s broader supply network: Construction of new Amneal facilities in India with Metsera-dedicated lines for peptide synthesis and sterile fill-finish manufacturing remains on track. Amneal also maintains extensive US manufacturing capabilities, with additional investments planned to expand this footprint. We plan to work actively with Amneal to optimize our commercial stage manufacturing footprint across Amneal’s US and global network.
Organizational Updates
Jon P. Stonehouse appointed Director: The Board of Directors of Metsera appointed Jon P. Stonehouse as a Class III director and member of the Audit Committee. Mr. Stonehouse is the Chief Executive Officer and Director of BioCryst Pharmaceuticals, Inc., a commercial stage biotechnology company, which he joined in January 2007. He has an extensive background in executive leadership roles in the biopharmaceutical industry.
Matthew Lang appointed Chief Legal Officer: Metsera appointed Matthew Lang as Chief Legal Officer and Secretary. Mr. Lang most recently served as the Chief Business Officer and Chief Legal Officer and Corporate Secretary of Lyell Immunopharma, Inc. from July 2023 to April 2025. Before joining Lyell, Mr. Lang held several executive officer positions at Myovant Sciences, Inc. between 2017 and 2023, most recently as Chief Administrative and Legal Officer. Earlier in his career Mr. Lang held roles of increasing seniority at Gilead Sciences, and was an attorney at Dechert, LLP. He received his B.A. in Classical Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.
About Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York City. For more information, please visit us at www.metsera.com and follow us on LinkedIn and X.
Metsera may use its website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investors & News section of its website at investors.metsera.com. In addition, you may sign up to automatically receive email alerts and other information about the Company by using the “Email Alerts” option on the Investors & Media page and submitting your email address.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the timelines and design of the Company’s clinical and pre-clinical trials and data releases; the Company’s product candidate pipeline and milestone events; potential benefits of treatment with the Company’s product candidates; anticipated market opportunity and strategy; our manufacturing efforts in collaboration with Amneal; and the Company’s future financial results and cash flow projections. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, our limited operating history; our ability to generate revenue or become profitable; failure to obtain additional capital when needed on acceptable terms or at all; raising additional capital may cause dilution to our stockholders or require us to relinquish rights to our technologies or product candidates; our dependence on the success of our product candidates; risks associated with preclinical and clinical development; difficulties or delays in the commencement or completion, or the termination or suspension, of clinical trials; our ability to timely enroll patients in our clinical trials; if our current or future product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with the regulatory approval processes of the FDA and comparable foreign authorities; risks associated with conducting clinical trials and preclinical studies outside of the United States; our reliance on third parties to conduct clinical trials and preclinical studies; our reliance on third parties for the manufacture and shipping of our product candidates; risks associated with our license and collaboration agreements and future strategic alliances; significant competition in our industry; product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated; our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personal; if we or our licensors are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or future product candidates or technology; risks associated with our common stock and the other important factors discussed under the caption “Risk Factors” in its filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, as updated by our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, once available, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at investors.metsera.com. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause the Company’s views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contact:
Jono Emmett
Metsera
media@metsera.com
| METSERA, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (in thousands, except share and per share data) | ||||||||
| As of | ||||||||
| (unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 588,335 | $ | 352,447 | ||||
| Prepaid expenses and other current assets | 6,403 | 6,686 | ||||||
| Total current assets | 594,738 | 359,133 | ||||||
| Property and equipment, net | 59 | 57 | ||||||
| Operating lease right-of-use asset | 1,215 | 1,385 | ||||||
| Intangible assets and goodwill | 93,126 | 90,413 | ||||||
| Other assets | 1,557 | — | ||||||
| Total assets | $ | 690,695 | $ | 450,988 | ||||
| Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 15,244 | $ | 20,837 | ||||
| Accrued expenses and other current liabilities | 31,031 | 17,877 | ||||||
| Note payable with related parties | 8,489 | 8,387 | ||||||
| Due to related parties | 320 | 392 | ||||||
| Operating lease liabilities, current | 727 | 714 | ||||||
| Contingent consideration, current | 34,930 | 19,100 | ||||||
| Total current liabilities | 90,741 | 67,307 | ||||||
| Deferred tax liabilities | 8,013 | 7,780 | ||||||
| Operating lease liabilities, noncurrent | 514 | 701 | ||||||
| Contingent consideration, noncurrent | 86,040 | 87,850 | ||||||
| Total liabilities | 185,308 | 163,638 | ||||||
| Redeemable convertible preferred stock, par value | — | 540,857 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, par value | — | — | ||||||
| Common stock, par value | 1 | — | ||||||
| Additional paid-in capital | 833,853 | 2,479 | ||||||
| Accumulated other comprehensive income (loss) | 5,267 | 1,160 | ||||||
| Accumulated deficit | (333,734 | ) | (257,146 | ) | ||||
| Total stockholders’ equity (deficit) | 505,387 | (253,507 | ) | |||||
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $ | 690,695 | $ | 450,988 | ||||
| METSERA, INC. | ||||||||
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | ||||||||
| (in thousands, except share and per share data) | ||||||||
| (unaudited) | ||||||||
| For the three months ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Acquired in-process research and development | $ | — | $ | 90 | ||||
| Research and development | 57,185 | 17,813 | ||||||
| General and administrative | 8,603 | 4,075 | ||||||
| Change in fair value of contingent consideration | 14,020 | (915 | ) | |||||
| Total operating expenses | 79,808 | 21,063 | ||||||
| Loss from operations | (79,808 | ) | (21,063 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | (101 | ) | — | |||||
| Foreign exchange loss | (1,590 | ) | (1 | ) | ||||
| Interest income | 4,911 | 893 | ||||||
| Loss before income taxes | (76,588 | ) | (20,171 | ) | ||||
| Income tax benefit | — | 291 | ||||||
| Net loss | $ | (76,588 | ) | $ | (19,880 | ) | ||
| Net loss per share of common stock, basic and diluted | $ | (1.03 | ) | $ | (1.44 | ) | ||
| Weighted-average shares of common stock outstanding, basic and diluted | 74,391,154 | 13,836,678 | ||||||
FAQ
What were Metsera's (MTSR) key financial results for Q1 2025?
What is the weight loss efficacy of Metsera's MET-097i drug candidate?
When will Metsera (MTSR) report VESPER-1 trial results for MET-097i?
What are the main drug candidates in Metsera's pipeline?
How much did Metsera raise in their IPO?
